Literature DB >> 26319115

Botanicals as "new" drugs: US development.

Freddie Ann Hoffman1.   

Abstract

Botanicals are ingredients that can be marketed as foods, drugs, cosmetics, and medical devices in the United States. When a botanical is intended to diagnose, treat, prevent, mitigate, or cure a disease, it is considered to be a "drug". This article reviews the US regulatory requirements for botanicals as "new" drugs. An overview of the regulatory principles used to determine product category and the basic elements of an Investigational New Drug application and New Drug Application with the US Food and Drug Administration are presented. This article is part of a Special Issue entitled "Botanicals for Epilepsy".
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Botanical; Drug development; Food and Drug Administration; IND; Investigational New Drug; NDA; New Drug Application; New drug approval; Regulation

Mesh:

Substances:

Year:  2015        PMID: 26319115     DOI: 10.1016/j.yebeh.2015.07.028

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  3 in total

1.  Translating Nature to Nurture: Back to the Future for "New" Epilepsy Therapies.

Authors:  Steven C Schachter
Journal:  Epilepsy Curr       Date:  2015 Nov-Dec       Impact factor: 7.500

Review 2.  Perspective on Improving the Relevance, Rigor, and Reproducibility of Botanical Clinical Trials: Lessons Learned From Turmeric Trials.

Authors:  Janet L Funk; Claus Schneider
Journal:  Front Nutr       Date:  2021-12-03

3.  Specialty molecules from plants and in vitro cultures as new drugs: regulatory considerations from flask to patient.

Authors:  Jinhui Dou; Pamela Weathers
Journal:  Plant Cell Tissue Organ Cult       Date:  2022-03-23       Impact factor: 2.726

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.